Suzhou Kintor Pharmaceutical Inc,

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Suzhou Kintor Pharmaceutical Inc, sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 7 completed early-phase tilt upper quartile by trial count

Suzhou Kintor Pharmaceutical Inc,: 8 sponsored US clinical trials, none currently recruiting.

Suzhou Kintor Pharmaceutical Inc, sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Castrate Resistant Prostate Cancer (mCRPC), with 1 trials.

Upper-quartile sponsor footprint

Suzhou Kintor Pharmaceutical Inc, sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 1

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

NCT05428449
COMPLETED Phase 2

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

NCT05218642
TERMINATED Phase 3

A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

NCT05009732
COMPLETED Phase 3

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

NCT04870606
COMPLETED Phase 1

the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

NCT04502901
COMPLETED Phase 2

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

NCT03899467
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

NCT04984707
COMPLETED Phase 1

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

NCT02826772

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2

Therapeutic Areas

Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1

How the Suzhou Kintor Pharmaceutical Inc, early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 7 completed (88%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC) (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Suzhou Kintor Pharmaceutical Inc,: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Suzhou Kintor Pharmaceutical Inc, sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Suzhou Kintor Pharmaceutical Inc,AB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Suzhou Kintor Pharmaceutical Inc, sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Suzhou Kintor Pharmaceutical Inc, sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Suzhou Kintor Pharmaceutical Inc, page

8 registered trials is a research-attention snapshot, not an endorsement of Suzhou Kintor Pharmaceutical Inc, or any single study.

  • None of Suzhou Kintor Pharmaceutical Inc,'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Metastatic Castrate Resistant Prostate Cancer (mCRPC) is the condition Suzhou Kintor Pharmaceutical Inc, studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Suzhou Kintor Pharmaceutical Inc, pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.